ClinicalTrials.gg
CompletedNCT01875367ChangHER-SCUpdated Apr 5, 2023Results posted

Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer

A Phase 3 interventional study of Trastuzumab Injectable Solution and Trastuzumab Injectable Product in Breast Cancer, sponsored by Spanish Breast Cancer Research Group. Completed at 27 sites in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-05.

Sponsored by Spanish Breast Cancer Research Group · Phase 3, Interventional, and Treatment

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
88th of 366
166 · median 61
Started
2013
with 25 others
Phase 3
60 of 374
3 open now
Registered
199th of 374
by date
Lead sponsor
6 of 374
Spanish Breast Cancer Research Group

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 88th largest by enrollment of the 366 interventional ones that give a count, is one of 26 that started in 2013, is one of 60 in phase 3, and was the 199th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

GEICAM/2012-07 is a study phase III, prospective, open, randomized, multicenter and national designed to assess patient preference for intravenous (IV) or subcutaneous (SC) of trastuzumab, and within the SC by the administration through the vial or device self-administration in patients with disseminated breast cancer HER2.

Read the detailed description

Approximately 195 patients will be included to receive subcutaneous trastuzumab a fixed dose of 600 mg every 3 weeks for 4 cycles (2 administered from the injection of a vial with a syringe and 2 with the injection device). Following administration of these four cycles, the patient will decide whether or not to continue with the subcutaneous formulation of trastuzumab every 3 weeks until progression (out of the study). Since the randomization in the study until the start with subcutaneous trastuzumab, patients will receive a treatment cycle of intravenous trastuzumab as usual.

Main objective: Proportion of patients indicate a preference for the use of subcutaneous vs intravenous trastuzumab.

This principal primary objective will be analyzed with the answers to questionnaire of experiences and preferences of the patients (Principal endpoint) The duration of the study has been estimated after 34 months.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Subcutaneous trastuzumab
  • Intravenous trastuzumab
  • HER2 positive
  • Advanced Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Woman, 18 years old or upper.
  • Patient with advanced breast cancer with human epidermal growth factor receptor 2 (HER 2) positive confirmed. The criteria for positivity HER 2 are:

    1. immuno-histochemistry (IHC) 3+ (>10% of tumor cells with complete and intense membrane staining)
    2. IHC 2+ with fluorescent in situ hybridization (FISH) / Chromogenic in situ hybridization (CISH) / silver-enhanced in situ hybridization (SISH) + for HER 2 amplification (*)
    3. FISH / CISH / SISH + for HER 2 amplification (*) (*) Defined as the ratio of copies of HER 2/neu and copies of centromere of chromosome 17 (CEP17)> 2.2, or a number of copies of HER 2/neu> 6, as per local laboratory criteria.
  • Patient receiving trastuzumab with or without chemotherapy or hormonal therapy for at least 4 months.
  • No evidence of disease progression (clinical and / or radiological) for at least 4 months before inclusion in the study and with a of at least 3 months.
  • Adequate performance status: (ECOG) \<2.
  • Adequate bone marrow function, liver and kidney
  • Proper cardiac function ( within normal limits the center, measured by echocardiography or MUGA).
  • The patient must have been informed of the study and must sign and date document for entry into the trial.
  • The patient must be willing and able to comply with study procedures and be available to answer the study questionnaires.

Exclusion criteria

Exclusion Criteria:

  • Patients with no advanced breast cancer.
  • Breast cancer patients with tumors HER 2-negative.
  • The patient has another active other than breast adenocarcinoma; are excluded the non-melanoma skin cancer or any other properly treated in situ neoplasia. Patients with a history of malignancy, if they bear> 5 years without evidence of disease could be included.
  • The patient has uncontrolled .
  • Concomitant administration, or in the 4 weeks prior to study entry, of other experimental treatment.
  • Known to trastuzumab or to any of its components.
  • Patients with severe dyspnea at rest or requiring supplemental oxygen.
  • Heart disease or serious medical pathological prevent trastuzumab administration: documented history of congestive cardiac insufficiency (CCI), high-risk arrhythmias uncontrolled angina requiring medication, valvular disease, history of myocardial infarction or evidence of transmural infarction on or hypertension poorly controlled.
  • Presence of any concomitant serious systemic disease that is incompatible with the study (at the discretion of the investigator).
  • The patient is pregnant or lactating. Women of should undergo pregnancy testing blood or urine within 14 days prior to inclusion as institutional rules and use a non-hormonal suitable: intrauterine device, barrier method (condom or diaphragm) also used in conjunction with spermicidal cream, total abstinence or surgical sterilization, during treatment with the study drugs and for 6 months following the end of treatment.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
166 participants (actual)

Study arms

  • Experimental
    Arm A: T-IV + T-SC vial + T-SC device

    Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with vial (Injectable Solution) x 2 cycles, followed by 600mg of T-SC with single injection device (SID) x 2 cycles.

    Drug: Trastuzumab Injectable Solution · Drug: Trastuzumab Injectable Product · Drug: Trastuzumab Injection

  • Experimental
    Arm B: T-IV + T-SC device + T-SC vial

    Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with single injection device (SID) x 2 cycles, followed by 600mg of T-SC with vial (Injectable Solution) x 2 cycles.

    Drug: Trastuzumab Injectable Solution · Drug: Trastuzumab Injectable Product · Drug: Trastuzumab Injection

Interventions

  • DrugTrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subcutaneous injection vial with a fixed dose of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) identical to that provided by the device. 3 weeks x 2 cycles.

    Also known as: Herceptin

  • DrugTrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Single injection device is provided and loaded with the mixture of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) and is ready for use. 3 weeks x 2 cycles

    Also known as: Herceptin

  • DrugTrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Powder for concentrate for solution for infusion. 1 cycle

    Also known as: Herceptin

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Subcutaneous vs. Intravenous Treatment Preference

    The percentage of patients who indicate a preference for the use of the intravenous vs subcutaneous administration of trastuzumab was analyzed with the answer to the questionnaire C2, question number 39 (All things considered, what method of administration do you prefer? Subcutaneous; Intravenous; No preference) of experiences and preferences of the patient.

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Percentage of Participants With Subcutaneous Treatment (Vial vs Device Administration) Preference

    The percentage of patients who indicate a preference for the use of SC administration by vial or device was analyzed. This was discussed in the answer to questionaire C3, question number 28 (All things considered, what method of administration do you prefer? Subcutaneous; Intravenous; No preference) of the questionnaire of experiences and preferences of the patient.

    Time frame: Up to 12 weeks

  2. Percentage of Medical Staff With Intravenous vs. Subcutaneous Preference

    The medical staff satisfaction was analyzed with the answers to question number 33a (Considering all aspects, with what method of administration were you more satisfied? Between Intravenous vs. Subcutaneous: Intravenous; Subcutaneous; No differences) of the questionnaire of experiences and preferences of the medical staff. Health care professionals were not considered enrolled, but did contribute to this assessment.

    Time frame: Up to 12 weeks

  3. Percentage of Medical Staff Subcutaneous Device vs. Vial Preference

    The medical staff satisfaction was analyzed with the answers to question number 33b (Considering all aspects, with what method of administration were you more satisfied? Between Vial vs. Device: Preferred device; Preferred vial; No Preference) of the questionnaire of experiences and preferences of the medical staff. Health care professionals were not considered enrolled, but did contribute to this assessment.

    Time frame: Up to 12 weeks

  4. Patient Time in Healthcare Unit and Sitting in Chair/Bed

    Time spent by patient in the healthcare unit: Time between entrance and exit from the healthcare unit. Time spent by patient sitting in the infusion/treatment chair/bed: Time between sitting and rising from the patient treatment chair/bed The data was collected by qualified observers from site staff that measured the time spent by healthcare professional using a chronometer, and write it down in the paper questionnaires or directly or after in the electronic case report form.

    Time frame: An average of 4 months

  5. The Number of Participants Who Experienced Adverse Events (AE)

    Safety was assessed by standard clinical and laboratory tests (haematology, serum chemistry). AE grade were defined by the NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) version 4.03.

    Time frame: Through study treatment, an average of 12 weeks

07

Results

Posted Feb 1, 2021
Limitations and caveats
We do not have longterm follow-up data of the SC-t efficacy. Device SC-t SID has not been commercialized. All patients had already been treated with IV-t for at least 4 months without disease progression prior to the study entry.

Participant flow

Eligible patients, from the randomization and before starting subcutaneous trastuzumab (SC-t), received an additional intravenous (IV-t) cycle. After receiving this cycle, patients started the treatment with the study medication, SC-t at a fixed dose of 600 mg every 3 weeks (+3 days) for 4 cycles (2 administered from the injection of a vial in a syringe and 2 with the single-use injection device \[SID\]), being randomized 1:1 in two arms of treatment without washout period.

Participant flow — Overall Study
MilestoneArm A: T-IV + T-SC Vial + T-SC DeviceArm B: T-IV + T-SC Device + T-SC Vial
Started8185
Completed7683
Not completed52
Withdrew: Not complete at least 2 questionaries42
Withdrew: Not receive study treatment10

Outcome measures

PrimaryPercentage of Participants With Subcutaneous vs. Intravenous Treatment Preference

The percentage of patients who indicate a preference for the use of the intravenous vs subcutaneous administration of trastuzumab was analyzed with the answer to the questionnaire C2, question number 39 (All things considered, what method of administration do you prefer? Subcutaneous; Intravenous; No preference) of experiences and preferences of the patient.

Time frame:
Up to 12 weeks
Reported as:
Count of participants · Participants
Percentage of Participants With Subcutaneous vs. Intravenous Treatment Preference
ParticipantsArm A: T-IV + T-SC Vial + T-SC DeviceArm B: T-IV + T-SC Device + T-SC Vial
Subcutaneous6671
Intravenous65
No preference47
SecondaryPercentage of Participants With Subcutaneous Treatment (Vial vs Device Administration) Preference

The percentage of patients who indicate a preference for the use of SC administration by vial or device was analyzed. This was discussed in the answer to questionaire C3, question number 28 (All things considered, what method of administration do you prefer? Subcutaneous; Intravenous; No preference) of the questionnaire of experiences and preferences of the patient.

Time frame:
Up to 12 weeks
Reported as:
Count of participants · Participants
Percentage of Participants With Subcutaneous Treatment (Vial vs Device Administration) Preference
ParticipantsArm A: T-IV + T-SC Vial + T-SC DeviceArm B: T-IV + T-SC Device + T-SC Vial
Device4644
Vial2020
No preference413
Not answered23
SecondaryPercentage of Medical Staff With Intravenous vs. Subcutaneous Preference

The medical staff satisfaction was analyzed with the answers to question number 33a (Considering all aspects, with what method of administration were you more satisfied? Between Intravenous vs. Subcutaneous: Intravenous; Subcutaneous; No differences) of the questionnaire of experiences and preferences of the medical staff. Health care professionals were not considered enrolled, but did contribute to this assessment.

Time frame:
Up to 12 weeks
Reported as:
Count of participants · Participants
Percentage of Medical Staff With Intravenous vs. Subcutaneous Preference
ParticipantsBoth Arms
Subcutaneous34
Intravenous0
No differences4
Not answered1
SecondaryPercentage of Medical Staff Subcutaneous Device vs. Vial Preference

The medical staff satisfaction was analyzed with the answers to question number 33b (Considering all aspects, with what method of administration were you more satisfied? Between Vial vs. Device: Preferred device; Preferred vial; No Preference) of the questionnaire of experiences and preferences of the medical staff. Health care professionals were not considered enrolled, but did contribute to this assessment.

Time frame:
Up to 12 weeks
Reported as:
Count of participants · Participants
Percentage of Medical Staff Subcutaneous Device vs. Vial Preference
ParticipantsBoth Arms
Preferred device20
Preferred vial11
No Preference8
SecondaryPatient Time in Healthcare Unit and Sitting in Chair/Bed

Time spent by patient in the healthcare unit: Time between entrance and exit from the healthcare unit. Time spent by patient sitting in the infusion/treatment chair/bed: Time between sitting and rising from the patient treatment chair/bed The data was collected by qualified observers from site staff that measured the time spent by healthcare professional using a chronometer, and write it down in the paper questionnaires or directly or after in the electronic case report form.

Time frame:
An average of 4 months
Reported as:
Mean · minutes
Patient Time in Healthcare Unit and Sitting in Chair/Bed
minutesBoth Arms: Intravenous-Trastuzumab (IV-t)Both Arms: Subcutaneous-Trastuzumab Vial (SC-t Vial)Boths Arms: Subcutaneous-Trastuzumab Device (SC-t SID)
Healthcare unit203 ± 123.57144.84 ± 121.99122.9 ± 112.33
Sitting in the infusion/treatment chair/bed100.01 ± 56.3431.6 ± 28.7424.75 ± 15.42
SecondaryThe Number of Participants Who Experienced Adverse Events (AE)

Safety was assessed by standard clinical and laboratory tests (haematology, serum chemistry). AE grade were defined by the NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) version 4.03.

Time frame:
Through study treatment, an average of 12 weeks
Reported as:
Count of participants · Participants
The Number of Participants Who Experienced Adverse Events (AE)
ParticipantsArm A: T-IV + T-SC Vial + T-SC DeviceArm B: T-IV + T-SC Device + T-SC Vial
The Number of Participants Who Experienced Adverse Events (AE)7684

Adverse events

Collected over Through study treatment, an average of 12 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: T-IV + T-SC Vial + T-SC Device0/81 (0%)2/81 (2.5%)76/81 (93.8%)
Arm B: T-IV + T-SC Device + T-SC Vial0/85 (0%)10/85 (11.8%)84/85 (98.8%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventArm A: T-IV + T-SC Vial + T-SC DeviceArm B: T-IV + T-SC Device + T-SC Vial
FeverGeneral disorders1/810/85
HematuriaRenal and urinary disorders1/810/85
Heart failureCardiac disorders0/811/85
Nodule in left breastReproductive system and breast disorders0/811/85
ColdInfections and infestations0/811/85
Nodule in right breastReproductive system and breast disorders0/811/85
Lack of strength in left legMusculoskeletal and connective tissue disorders0/811/85
Catheter related infection (Bacteriemia)Infections and infestations0/811/85
StrokeNervous system disorders0/811/85
Surgery for surgical castrationReproductive system and breast disorders0/811/85
Most frequent other events
Showing 10 of 39
Most frequent other events
EventArm A: T-IV + T-SC Vial + T-SC DeviceArm B: T-IV + T-SC Device + T-SC Vial
AnemiaBlood and lymphatic system disorders27/8132/85
Creatinine increasedInvestigations13/8117/85
Aspartate aminotransferase increasedInvestigations15/8117/85
White blood cells decreasedInvestigations15/8117/85
Alanine aminotransferase increasedInvestigations16/8110/85
FatigueGeneral disorders10/8116/85
Alkaline phosphatase increasedInvestigations12/8115/85
Neutrophil count decreasedInvestigations13/8113/85
Injection site reactionGeneral disorders9/816/85
Platelet count decreasedInvestigations4/818/85

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm A: T-IV + T-SC Vial + T-SC DeviceArm B: T-IV + T-SC Device + T-SC VialTotal
Median63 (35 to 93)58 (38 to 85)60 (35 to 93)
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: T-IV + T-SC Vial + T-SC DeviceArm B: T-IV + T-SC Device + T-SC VialTotal
Female8185166
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm A: T-IV + T-SC Vial + T-SC DeviceArm B: T-IV + T-SC Device + T-SC VialTotal
Caucasian7883161
Black101
Hispanic101
Arabian123
Menopausal status
Menopausal status(Participants)Arm A: T-IV + T-SC Vial + T-SC DeviceArm B: T-IV + T-SC Device + T-SC VialTotal
Premenopausal81220
Postmenopausal7373146
Eastern Cooperative Oncology Group (ECOG) performance status
Eastern Cooperative Oncology Group (ECOG) performance status(Participants)Arm A: T-IV + T-SC Vial + T-SC DeviceArm B: T-IV + T-SC Device + T-SC VialTotal
ECOG 06361124
ECOG 1172441
ECOG 2101
Estrogen Receptor
Estrogen Receptor(Participants)Arm A: T-IV + T-SC Vial + T-SC DeviceArm B: T-IV + T-SC Device + T-SC VialTotal
Positive4660106
Negative352560
Progesterone Receptor
Progesterone Receptor(Participants)Arm A: T-IV + T-SC Vial + T-SC DeviceArm B: T-IV + T-SC Device + T-SC VialTotal
Negative503888
Positive314778
Time with IV trastuzumab for metastasis at registration
Time with IV trastuzumab for metastasis at registration(years)Arm A: T-IV + T-SC Vial + T-SC DeviceArm B: T-IV + T-SC Device + T-SC VialTotal
Median1.9 (0.35 to 13.67)1.78 (0.34 to 14.05)1.8 (0.34 to 14.05)

9 further baseline measures are reported on the registry.

08

Study locations

27 sites
  • Hospital General Universitario de Granollers
    Granollers, Barcelona 08402, Spain
  • Hospital de Mataró
    Mataró, Barcelona 08304, Spain
  • Hospital Sant Joan Despí Moises Broggi
    Sant Joan Despí, Barcelona 08970, Spain
  • Hospital Virgen del Puerto de Plasencia
    Plasencia, Cáceres 10600, Spain
  • Hospital de Manacor
    Manacor, Illes Balears 07500, Spain
  • Hospital Universitario de Fuenlabrada
    Fuenlabrada, Madrid 28924, Spain
  • Hospital Universitario Severo Ochoa
    Leganés, Madrid 28911, Spain
  • Hospital Univesitario Quirón Madrid
    Pozuelo De Alarcón, Madrid 28223, Spain
  • Hospital Universitario Santa Lucía
    Cartagena, Murcia 30202, Spain
  • Hospital Costa del Sol
    Marbella, Málaga 29603, Spain
  • Hospital Universitario San Joan de Reus
    Reus, Tarragona 43201, Spain
  • Hospital del Mar
    Barcelona, 08003, Spain
  • Hospital Clinic i Provincial
    Barcelona, 08036, Spain
  • Hospital Germans Trias i Pujol
    Barcelona, 08916, Spain
  • Hospital Universitario Virgen de las Nieves
    Granada, 18014, Spain
  • Hospital Universitario Arnau de Vilanova de Lleida
    Lleida, 25198, Spain
  • Hospital Universitario Lucus Augusti
    Lugo, 27004, Spain
  • Hospital Universitario La Princesa
    Madrid, 28006, Spain
  • Hospital General Universitario Gregorio Marañón
    Madrid, 28007, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28021, Spain
  • Hospital Universitario de Salamanca
    Salamanca, 37007, Spain
  • Hospital Universitario Virgen de la Macarena
    Sevilla, 41009, Spain
  • Hospital Universitario Virgen del Rocío
    Sevilla, 41013, Spain
  • Hospital Virgen de la Salud
    Toledo, 45004, Spain
  • Hospital Clínico Universitario de Valencia
    Valencia, 46010, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, 50009, Spain
  • Hospital Nuestra Señora de Sonsoles
    Ávila, 05004, Spain
09

References and documents

Publications

  • Ciruelos EM, Montano A, Rodriguez CA, Gonzalez-Flores E, Lluch A, Garrigos L, Quiroga V, Anton A, Malon D, Chacon JI, Velasco M, Gonzalez-Cortijo L, Jolis L, Echarri MJ, Munoz M, Pascual T, Amigo Y, Casas M, Carrasco E, Casas A. Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07). Eur J Cancer Care (Engl). 2020 Jul;29(4):e13253. doi: 10.1111/ecc.13253. Epub 2020 Jun 23. PubMed 32578279 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Nov 2016, 38 months.

Results were first posted in Feb 2021, 4 years 2 months after primary completion.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's 38 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2013
First posted
Jun 11, 2013
StartActual
Sep 18, 2013
Primary completionActual
Nov 30, 2016
CompletionActual
Apr 30, 2018
Results first posted
Feb 1, 2021
Last update
Apr 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01875367
Lead sponsor
Spanish Breast Cancer Research Group
Responsible party
Sponsor
First posted
Jun 11, 2013
Start date
Sep 18, 2013
Primary completion
Nov 30, 2016
Completion
Apr 30, 2018
Results posted
Feb 1, 2021
Last update
Apr 5, 2023

Study contacts

Study Director
study director · Hospitales Universitarios Virgen del Rocío

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion